BenchSci vs Causaly (2026)
BenchSci and Causaly help scientists investigate biomedical questions using literature, knowledge graphs and internal evidence. BenchSci's EMET emphasizes an integrated research workspace connected to experimental data; Causaly combines research agents, specialized graphs and repeatable scientific workflows. EMET selects tools and assembles analyses for target discovery, experimental planning and drug safety research. Organizations can connect laboratory systems, upload documents and maintain a private research graph. Academic access is limited and free for eligible users, while enterprise deployments add scientific support and customized workflows. BenchSci's claim that EMET does not hallucinate conflicts with terms acknowledging incorrect outputs, so its evidence remains material for scientist review. Causaly combines Bio Graph, Pipeline Graph and Agentic Research for biological investigation and competitive analysis. Deep Research uses a Principal Investigator Agent to critique evidence and request further work before a report reaches the scientist. Causaly Research starts at $99 per month, while private data integration and enterprise workflows have separate commercial scope. Customer productivity accounts lack controlled measurement detail. BenchSci fits research groups connecting experimental knowledge and literature within a supported workspace. Causaly fits teams organizing research around biological relationships, competitive pipelines and reusable methods, with individual subscriptions available alongside enterprise deployment. Both produce research material for scientific interpretation and subsequent testing.
- Experimental planning and target research need a shared workspace.
- Internal laboratory systems should connect to a private research graph.
- Eligible academic users need a limited free entry option.
- An enterprise wants scientific support with configured research workflows.
- Biological and competitive pipeline relationships are recurring research needs.
- A team's methods should become repeatable scientific workflows.
- Researchers want evidence critique before reviewing a generated report.
- An individual researcher wants a priced monthly entry plan.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. BenchSci and Causaly are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | BenchSci | Causaly |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2015 | 2018 |
| Headquarters | Toronto, Canada | London, United Kingdom |
| Website | benchsci.com | causaly.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
BenchSci develops EMET, an AI research environment for scientists in biopharma and academia. The platform combines scientific literature, experimental databases and internal research with a biomedical knowledge graph. Researchers ask questions in ordinary language, and agents select tools, search evidence and assemble analyses for work such as target discovery, experimental planning and drug safety research.
Source: AI Health Index, October 2026
Causaly supplies scientific AI software for pharmaceutical, biotechnology and academic research. Its agents combine biomedical literature, knowledge graphs and an organization's internal evidence to investigate questions, compare findings and produce assessments. Bio Graph maps biological relationships, Pipeline Graph supports competitive research, and Scientific Workflows turns a team's methods into repeatable research tasks.
Source: AI Health Index, October 2026
Questions buyers ask
How do BenchSci and Causaly work with the EHR?
For BenchSci, the July 2026 internal data release names live connections to Benchling, Veeva, electronic laboratory notebooks, D360 and GDB, alongside document uploads and a private knowledge graph option. It distinguishes reading existing systems from ingesting material into that graph.
Causaly also demonstrates access through Microsoft 365 Copilot. Its enterprise data fabric supports APIs and connectors for customer stores in Azure, Google Cloud and AWS, with custom connections available for other material. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
How are BenchSci and Causaly priced and sold?
In BenchSci's case, enterprise access is custom priced and starts with a free pilot. The enterprise package includes broader content access, internal data connections, advanced reasoning, team controls, onboarding and dedicated support.
For Causaly, a Team plan is advertised at $250 per seat monthly for three to fifteen seats, with pooled credits, but remains marked as coming soon in October 2026. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
How do BenchSci and Causaly handle patient data?
With BenchSci, the privacy notice separately requires consent before identifiable personal information trains external models, while allowing certain internal research uses. Routine retention follows purpose and legal need rather than a fixed deletion schedule; records associated with safety incidents have a minimum five year period.
Causaly Research's newer terms distinguish uploaded customer content from prompts, usage and personalization information; protection for performance data is broader on the Team plan than on individual subscriptions. The processing addendum sets a termination return or deletion process within 90 days, subject to legal retention. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
Which settings and specialties do BenchSci and Causaly cover?
For BenchSci, the Cape Town tuberculosis example and the kidney experiment case support actual use in two research settings. Sanofi's ASCEND license extends to its global preclinical organization across therapeutic areas, although that agreement does not validate every newer EMET workflow.
With Causaly, the broader catalog also covers indication expansion and competitive intelligence, without equivalent evaluation for every workflow. Individual researchers and smaller teams now have a separate access route, but their subscription availability does not itself establish performance across every scientific specialty. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
BenchSci is based in Toronto, Canada, and Causaly in London, United Kingdom. Enterprise prices are negotiated for both. Sanofi's ASCEND license concerns an earlier BenchSci offering; it is not an EMET outcome study. Causaly's advertised Team subscription remains forthcoming.